Izlaganje sa skupa
DULOXETINE IN MAJOR DEPRESSED PATIENTS RESISTANT TO SSRIS AND/OR VENLAFAXINE
William Pitchot
; University of Liège, Department of Psychiatry, Liège, Belgium
Gaby Scantamburlo
; University of Liège, Department of Psychiatry, Liège, Belgium
Marc Ansseau
; University of Liège, Department of Psychiatry, Liège, Belgium
Sažetak
Several acute depression trials suggest that only 35% of the patients achieve remission state with antidepressant monotherapy.
An increasing body of evidence is emerging suggesting that multi-action antidepressants might be more effective in treatmentresistant
depressed patients than single-action agents. In this context, the purpose of the study was to assess the effectiveness of
duloxetine in treatment-resistant major depressed outpatients.
We performed a retrospective study assessing the efficacy of duloxetine in major depressed outpatients who did not achieve full
symptom remission (CGI-S (severity) ≥ 3) after treatment of adequate dose and duration (more than 8 weeks) with at least either one
SSRI or the SNRI venlafaxine. We excluded patients with a severe medical illness and a personality disorder. CGI-S was used as a
measure of symptom severity and administered before the prescription of duloxetine and 6 weeks later. The sample included 29
patients (9 M, 20 F). We observed a very significant decrease in CGI-S scores (4,86 ± 0.51 to 2,17 ± 1,44, p<0.0001) after treatment
with duloxetine (dose between 60 and 120 mg). Remission was achieved in 48 % of the patients. The tolerance was excellent. This
study suggests the potential interest of duloxetine in some treatment-resistant depressed patients.
Ključne riječi
major depression; remission; SSRI; SNRI , duloxetine
Hrčak ID:
262750
URI
Datum izdavanja:
14.9.2010.
Posjeta: 195 *